IMUX — IMMUNIC, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1280776 ·
Last close
$13.97
Market Cap
$190.29M
52W High
$15.84
52W Low
$9.25
ADV30
170,803
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -33,235,000 | -32,588,000 | 189,742,000 | 186,629,000 | 38,509,000 |
| Dec 2025 | 0 | — | -23,327,000 | -19,300,000 | 24,052,000 | 15,483,000 | 30,725,000 |
| Sep 2025 | 0 | — | -25,993,000 | -25,579,000 | 40,704,000 | 35,132,000 | 30,205,000 |
| Jun 2025 | 0 | — | -27,083,000 | -26,820,000 | 61,429,000 | 55,310,000 | 27,518,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,331,000
Investing CF
$-116,000
Financing CF
$65,577,000
CapEx
$-116,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.89
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-641,159,000
Inventory
—
Receivables
$354,000
ST Investments
—
EBIT TTM
$-109,638,000
Pretax Income TTM
$-104,287,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -103,228,000 | -97,172,000 | 24,052,000 | 30,725,000 | — | -85,806,000 |
| Dec 2024 | 0 | -98,052,000 | -100,507,000 | 40,868,000 | 22,439,000 | — | -84,766,000 |
| Dec 2023 | 0 | -99,223,000 | -93,612,000 | 54,299,000 | 25,368,000 | — | -70,828,000 |
| Dec 2022 | 0 | -86,518,000 | -120,407,000 | 127,753,000 | 14,069,000 | — | -65,144,000 |
TTM Snapshot
Revenues TTM
$1,782,000
NetIncome TTM
$-87,653,000
OpCashFlow TTM
$0
Assets (Latest)
$40,868,000
Forward EPS
$-3.63
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $13.97 · call volume: 64 · put volume: 2Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| WHWK | Whitehawk Therapeutics, Inc. | $190.39M | $3.85 | — |
| ANTX | AN2 Therapeutics, Inc. | $192.69M | $5.35 | — |
| RNA | Atrium Therapeutics, Inc. | $194.15M | $11.35 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $194.44M | $3.86 | — |
| NERV | Minerva Neurosciences, Inc. | $185.42M | $3.98 | — |
News headlines (Yahoo Finance, 1h cache)
Immunic to Participate in Investor Conferences in July
2026-07-09 10:30 · Yahoo
Immunic to Participate in Investor, Industry and Scientific Conferences in June
2026-06-10 10:30 · Yahoo
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
2026-05-28 14:29 · Yahoo
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
2026-05-28 10:30 · Yahoo
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
2026-05-27 13:06 · Yahoo
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
2026-05-27 10:30 · Yahoo
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
2026-05-27 10:17 · Yahoo
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
2026-05-19 13:33 · Yahoo
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
2026-05-19 10:30 · Yahoo
Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?
2026-05-17 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.